{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T06:05:13Z","timestamp":1784613913839,"version":"3.55.0"},"reference-count":25,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T00:00:00Z","timestamp":1784592000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Optimal antithrombotic therapy following transcatheter mitral valve repair (TMVR\/TEER) in patients with atrial fibrillation remains uncertain, with substantial practice variation and reliance on nonrandomized data.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a systematic review and network meta-analysis of observational studies evaluating antithrombotic strategies after TMVR\/TEER with atrial fibrillation. Antithrombotic regimens were harmonized into two main categories: oral anticoagulation [OAC; including vitamin K antagonists [VKAs] and direct oral anticoagulants [DOACs]] and antiplatelet therapy (APT; including aspirin or clopidogrel, alone or in combination). Outcomes of interest were ischemic stroke, major bleeding, and all-cause mortality. Pairwise and network random-effects models were applied to derive odds ratios (ORs) with 95% confidence intervals (CIs).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Four multicenter observational cohorts (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u20092,098) were included. Across comparisons, OAC strategies demonstrated a favorable profile compared with APT for bleeding risk reduction, while DOACs showed heterogeneous results depending on comparator drug and study region (phenprocoumon in Europe vs. warfarin in the U.S.). Mortality findings consistently favored OAC (particularly DOACs) potential benefits over APT. For stroke, OAC (phenprocoumon) showed better ischemic prevention, indicating more effectiveness in minimizing stroke risk compared with APT. Network geometry was limited, with most contrasts informed by only one or two studies.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In patients undergoing TMVR\/TEER with atrial fibrillation, OAC strategies appeared to be associated with lower bleeding risk and potentially favorable mortality outcomes compared with antiplatelet therapy. However, conclusions regarding comparative efficacy, particularly for stroke prevention, should be interpreted cautiously due to the limited number of studies and the observational nature of the available evidence. Thus, the evidence base remains limited by observational design, heterogeneous comparators, and inconsistent outcome definitions. Randomized trials are urgently needed to guide antithrombotic management in this high-risk population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcvm.2026.1743097","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:36:02Z","timestamp":1784612162000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of different antithrombotic treatment regimens in patients undergoing transcatheter mitral valve repair and atrial fibrillation; A meta-analysis and systematic review"],"prefix":"10.3389","volume":"13","author":[{"given":"Fuli","family":"Zhu","sequence":"first","affiliation":[{"name":"Department of Cardiology, Beijing Luhe Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Clinical Medicine, Chengde Medical University","place":["Chengde City, Hebei, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"He","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Beijing Luhe Hospital, Capital Medical University","place":["Beijing, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.jcin.2018.12.012","article-title":"The prevalence and impact of atrial fibrillation on 1-year outcomes in patients undergoing transcatheter mitral valve repair: results from the society of thoracic surgeons\/American College of Cardiology transcatheter valve therapy registry","volume":"12","author":"Arora","year":"2019","journal-title":"JACC Cardiovasc Interv"},{"key":"B2","doi-asserted-by":"publisher","first-page":"5044","DOI":"10.3390\/jcm10215044","article-title":"Impact of rhythm vs. Rate control in atrial fibrillation on the long-term outcome of patients undergoing transcatheter edge-to-edge mitral valve repair","volume":"10","author":"Waechter","year":"2021","journal-title":"J Clin Med"},{"key":"B3","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1007\/s10741-020-10051-z","article-title":"Impact of atrial fibrillation on the outcomes of transcatheter mitral valve repair using MitraClip: a systematic review and meta-analysis","volume":"26","author":"Shah","year":"2021","journal-title":"Heart Fail Rev"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1161\/CIRCULATIONAHA.121.054305","article-title":"Antithrombotic therapy in patients undergoing transcatheter interventions for structural heart disease","volume":"144","author":"Calabr\u00f2","year":"2021","journal-title":"Circulation"},{"key":"B5","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1002\/clc.24017","article-title":"Anticoagulation therapy and clinical outcomes following transcatheter mitral valve repair for patients with mitral regurgitation: a meta-analysis","volume":"46","author":"Zhang","year":"2023","journal-title":"Clin Cardiol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s11886-024-02132-4","article-title":"Cerebral embolic protection: is there a benefit for left atrial and mitral valve procedures?","volume":"26","author":"Besir","year":"2024","journal-title":"Curr Cardiol Rep"},{"key":"B7","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1007\/s00392-022-01988-2","article-title":"Real-World anticoagulatory treatment after percutaneous mitral valve repair using MitraClip: a retrospective, observational study on 1300 patients","volume":"111","author":"Hohmann","year":"2022","journal-title":"Clin Res Cardiol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"366","DOI":"10.3390\/jcdd9110366","article-title":"Antithrombotic treatment and its association with outcome in a multicenter cohort of transcatheter edge-to-edge mitral valve repair patients","volume":"9","author":"Waechter","year":"2022","journal-title":"J Cardiovasc Dev Dis"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e038834","DOI":"10.1161\/JAHA.124.038834","article-title":"Direct oral anticoagulants versus vitamin K antagonists after mitral valve transcatheter edge-to-edge repair","volume":"14","author":"Schipper","year":"2025","journal-title":"J Am Heart Assoc"},{"key":"B10","doi-asserted-by":"publisher","first-page":"955","DOI":"10.1016\/S0140-6736(13)62343-0","article-title":"Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis","volume":"383","author":"Ruff","year":"2014","journal-title":"Lancet"},{"key":"B11","doi-asserted-by":"publisher","first-page":"e026666","DOI":"10.1161\/JAHA.122.026666","article-title":"Direct oral anticoagulants versus warfarin in patients with atrial fibrillation and valve replacement or repair","volume":"11","author":"Mentias","year":"2022","journal-title":"J Am Heart Assoc"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.1016\/j.jacc.2016.12.038","article-title":"Non-Vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and valvular heart disease","volume":"69","author":"Renda","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"B13","doi-asserted-by":"publisher","first-page":"823","DOI":"10.1056\/NEJMoa1501035","article-title":"Perioperative bridging anticoagulation in patients with atrial fibrillation","volume":"373","author":"Douketis","year":"2015","journal-title":"N Engl J Med"},{"key":"B14","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1590\/s0066-782x2010000100008","article-title":"Warfarin and phenprocoumon: experience of an outpatient anticoagulation clinic","volume":"94","author":"Leiria","year":"2010","journal-title":"Arq Bras Cardiol"},{"key":"B15","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S0140-6736(10)61194-4","article-title":"Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial","volume":"376","author":"Wallentin","year":"2010","journal-title":"Lancet"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1056\/NEJMoa1817083","article-title":"Antithrombotic therapy after acute coronary syndrome or PCI in atrial fibrillation","volume":"380","author":"Lopes","year":"2019","journal-title":"N Engl J Med"},{"key":"B17","doi-asserted-by":"publisher","first-page":"e003725","DOI":"10.1161\/JAHA.116.003725","article-title":"Effectiveness and safety of dabigatran, rivaroxaban, and apixaban versus warfarin in nonvalvular atrial fibrillation","volume":"5","author":"Yao","year":"2016","journal-title":"J Am Heart Assoc"},{"key":"B18","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1161\/CIRCULATIONAHA.116.021890","article-title":"On-Treatment outcomes in patients with worsening renal function with rivaroxaban compared with warfarin: insights from ROCKET AF","volume":"134","author":"Fordyce","year":"2016","journal-title":"Circulation"},{"key":"B19","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","article-title":"Definition of Major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients","volume":"3","author":"Schulman","year":"2005","journal-title":"J Thromb Haemost"},{"key":"B20","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the bleeding academic research consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0735-1097(88)90158-1","article-title":"Thrombolysis in myocardial infarction (TIMI) trial\u2013phase I: hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase","volume":"11","author":"Rao","year":"1988","journal-title":"J Am Coll Cardiol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1093\/biomet\/70.1.41","article-title":"The central role of the propensity score in observational studies for causal effects","volume":"70","author":"Rosenbaum","year":"1983","journal-title":"Biometrika"},{"key":"B23","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An Introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behavioral Res"},{"key":"B24","doi-asserted-by":"publisher","first-page":"e35","DOI":"10.1161\/CIR.0000000000000932","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: executive summary","volume":"143","author":"Otto","year":"2021","journal-title":"Circulation"},{"key":"B25","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1002\/jrsm.1167","article-title":"Automated generation of node splitting models for assessment of inconsistency in network meta-analysis","volume":"7","author":"Valkenhoef","year":"2016","journal-title":"Res Synth Method"}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1743097\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T05:36:03Z","timestamp":1784612163000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2026.1743097\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":25,"alternative-id":["10.3389\/fcvm.2026.1743097"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2026.1743097","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,21]]},"article-number":"1743097"}}